🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. BCMA CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions

    phase 2 small molecule active

    1 trial

  2. BCMA/CD3 bispecific antibody (CM336)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solitary Bone Plasmacytoma

    phase 2 small molecule active

    1 trial

  3. BGB-A317

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  4. BI-754091 plus afatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule completed

    1 trial

  5. BM-MSCs

    The First People's Hospital of Lianyungang

    Kidney Transplantation

    phase 2 other active

    2 trials

  6. BMMNCs

    Hospital Authority, Hong Kong

    Retinitis Pigmentosa

    phase 2 mab active

    1 trial

  7. BMSC transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 other active

    1 trial

  8. BPF-CCRT (run-in)

    Hospital Authority, Hong Kong

    Stage III Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  9. Baricitinib 2 MG [Olumiant]

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  10. Baritinib

    The First People's Hospital of Lianyungang

    Intracerebral Hemorrhage

    phase 2 small molecule completed

    1 trial

  11. Becotatug Vedotin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  12. Becotatug Vedotin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Penile Cancer

    phase 2 small molecule active

    1 trial

  13. Becotatug Vedotin

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  14. Bedaquiline (B)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tuberculosis, Pulmonary

    phase 2 small molecule active

    1 trial

  15. Befotertinib combined Bevacizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    EGFR

    phase 2 small molecule active

    1 trial

  16. Benmelstobart

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. Bevacizumab

    The First People's Hospital of Lianyungang

    Malignant Pleural Effusion

    phase 2 small molecule active

    1 trial

  18. Bevacizumab

    The First People's Hospital of Lianyungang

    Lung, Carcinoma

    phase 2 small molecule active

    1 trial

  19. Bevacizumab

    The First People's Hospital of Lianyungang

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  20. Bevacizumab Biosimilar IBI305

    The First People's Hospital of Lianyungang

    Post-orthotopic Liver Transplantation

    phase 2 small molecule active

    1 trial

  21. Bevacizumab combined with Oxaliplatin and TAS-102

    The First People's Hospital of Lianyungang

    Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  22. Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  23. Bicalutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  24. BinD19

    The First People's Hospital of Lianyungang

    Relapsed B-cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources